Dr. Kenneth B. Graham
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,789
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
NY license 224987
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Shore University Hospital Manhasset, NY
Medical groups
- Long Island Vitreo Retinal Consultants PC (20 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,789
- Services billed
- 58,920
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 22,860 | 124 |
| Injection, aflibercept, 1 mg | 4,724 | 521 |
| Imaging of retina | 4,344 | 1,618 |
| Injection of drug into eye | 2,906 | 723 |
| Established patient problem focused exam of visual system | 1,411 | 806 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 1,236 | 108 |
| Injection, ranibizumab, 0.1 mg | 1,055 | 99 |
| Extended exam of the back part of the eye with retinal drawing | 932 | 683 |
| Established patient office or other outpatient visit, 20-29 minutes | 915 | 666 |
| Extended exam of the back part of the eye with optic nerve drawing | 566 | 420 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Great Neck, NY | 161 |
| Timolol Maleate Other prescribers in Great Neck, NY | 53 |
| Ofloxacin Other prescribers in Great Neck, NY | 51 |
| Latanoprost Other prescribers in Great Neck, NY | 49 |
| Ketorolac Tromethamine Other prescribers in Great Neck, NY | 41 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Great Neck, NY | 27 |
| Brimonidine Tartrate Other prescribers in Great Neck, NY | 26 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Great Neck, NY | 18 |
| Dorzolamide Hcl Other prescribers in Great Neck, NY | 18 |
| Difluprednate | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 16 payments worth $764 in total to this clinician.
| Genentech USA, Inc. | $163 |
|---|---|
| Glaukos Corporation | $161 |
| Bausch & Lomb Americas Inc. | $150 |
| Regeneron Healthcare Solutions, Inc. | $144 |
| Tarsus Pharmaceuticals, Inc. | $124 |
| Astellas Pharma US Inc | $22.43 |
| Food and Beverage | $764 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $199,958 in research payments for these studies, mostly to the institutions running them.
- A Phase 1 SAD MD in Diabetic Macular Edema
Genentech, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Bayer HealthCare Pharmaceuticals Inc. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.